Clinical-stage global biopharmaceutical company Zenas BioPharma Inc. (ZBIO) is positioned for a catalyst-rich stretch as it advances obexelimab, a bifunctional monoclonal antibody targeting CD19 and Fc?RIIb, through three late-stage trials.
The company expects topline results from its pivotal Phase 3 INDIGO trial in IgG4-related disease (IgG4-RD) around year-end 2025. This global, randomized, placebo-controlled study is the largest conducted to date in IgG4-RD and is designed to evaluate obexelimab's efficacy and safety in a population with no FDA-approved therapies.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.